Form 4 for AKBA Akebia Therapeutics, Inc.
Accepted 2026-08-10 16:08:41 ET · period of report 2026-08-06 · accession 0001591467-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-10 16:08 | 2026-08-06 | AKBA | Butler John P. | CEO, Pres, Dir | M - OptEx | $0.63 | +350.0K | 3.72M | +10% | +$220.5K |
| D | 2026-08-10 16:08 | 2026-08-06 | AKBA | Butler John P. | CEO, Pres, Dir | M - OptEx | $0.00 | -350.0K | 525.0K | -40% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-06 | M | A | 350,000 | $0.63 | 3,718,564 | D | — | — | (F1) Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2026 under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. |
| 2 | Derivative | Stock Option (Right to buy) | 2026-08-06 | M | D | 350,000 | $0.00 | 525,000 | D | $0.63 · — to 2033-01-31 | 350,000 Common Stock | (F2) The options were granted by the Issuer on January 31, 2023 and vest over four years: 25% of the options vested on January 31, 2024 with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. |